✦ LIBER ✦
A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses
✍ Scribed by Jiri Beran; Ibrahim A. Abdel-Messih; Jolana Raupachova; Lenka Hobzova; Elena Fragapane
- Book ID
- 114123034
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 137 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0149-2918
No coin nor oath required. For personal study only.